HIGHGLYCAN

Methods for high-throughput (HTP) analysis of protein glycosylation

 Coordinatore ACADEMISCH ZIEKENHUIS LEIDEN 

 Organization address address: Albinusdreef 2
city: LEIDEN
postcode: 2333 ZA

contact info
Titolo: Dr.
Nome: Manfred
Cognome: Wuhrer
Email: send email
Telefono: 31715265081
Fax: 31715266907

 Nazionalità Coordinatore Netherlands [NL]
 Totale costo 7˙799˙296 €
 EC contributo 5˙998˙972 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2011-two-stage
 Funding Scheme CP-FP
 Anno di inizio 2011
 Periodo (anno-mese-giorno) 2011-11-01   -   2016-10-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    ACADEMISCH ZIEKENHUIS LEIDEN

 Organization address address: Albinusdreef 2
city: LEIDEN
postcode: 2333 ZA

contact info
Titolo: Dr.
Nome: Manfred
Cognome: Wuhrer
Email: send email
Telefono: 31715265081
Fax: 31715266907

NL (LEIDEN) coordinator 1˙638˙960.80
2    LUDGER LTD

 Organization address address: Culham Science centre- Building E1
city: ABINGDON
postcode: OX14 3EB

contact info
Titolo: Dr.
Nome: Daryl
Cognome: Fernandes
Email: send email
Telefono: +44 1865 408554
Fax: +44 870 163 4620

UK (ABINGDON) participant 1˙011˙232.00
3    GENOS DOO ZA VJESTACENJE I ANALIZU

 Organization address address: Vatrogasna 112
city: Osijek
postcode: 31000

contact info
Titolo: Dr.
Nome: Gordan
Cognome: Lauc
Email: send email
Telefono: 38512352660
Fax: 3852352663

HR (Osijek) participant 988˙579.60
4    National Institute for Bioprocessing Research and Training Ltd

 Organization address address: "Engineering Building, Belfield 125"
city: Dublin
postcode: 4

contact info
Titolo: Prof.
Nome: Pauline Mary
Cognome: Rudd
Email: send email
Telefono: 35312158143

IE (Dublin) participant 589˙120.00
5    BIA SEPARATIONS DOO

 Organization address address: MIRCE 21
city: AJDOVSCINA
postcode: 5270

contact info
Titolo: Dr.
Nome: Jana
Cognome: Vidi?
Email: send email
Telefono: +38 614 265649

SI (AJDOVSCINA) participant 484˙400.00
6    THE UNIVERSITY OF EDINBURGH

 Organization address address: OLD COLLEGE, SOUTH BRIDGE
city: EDINBURGH
postcode: EH8 9YL

contact info
Titolo: Ms.
Nome: Gemma
Cognome: Scott-Wood
Email: send email
Telefono: 441312000000

UK (EDINBURGH) participant 468˙680.00
7    GLYXERA GMBH

 Organization address address: Leipziger Strasse 44
city: MAGDEBURG
postcode: 39120

contact info
Titolo: Mr.
Nome: Thomas
Cognome: Hermsdorfer
Email: send email
Telefono: 493916000000
Fax: +49391 6117255

DE (MAGDEBURG) participant 374˙100.00
8    MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.

 Organization address address: Hofgartenstrasse 8
city: MUENCHEN
postcode: 80539

contact info
Titolo: Dr.
Nome: Erdmann
Cognome: Rapp
Email: send email
Telefono: +49 391 6110314

DE (MUENCHEN) participant 328˙100.00
9    MP BIOMEDICALS SARL

 Organization address address: RUE JEAN GEILER DE KAYSERSBERG
city: ILLKIRCH-GRAFFENSTADEN
postcode: 67400

contact info
Titolo: Dr.
Nome: Miodrag
Cognome: Micic
Email: send email
Telefono: +1 949 981 1068
Fax: +1 949 859 5095

FR (ILLKIRCH-GRAFFENSTADEN) participant 115˙800.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

regard    addition    biomarkers    glycomic    individuals    industrial    reliably    glycan    diabetes    services    samples    preparation    multitude    diseases    glycoanalytical    glycosylation    proteins    disease    scientists    structures    complexity    disorders    glycome    cancer    highglycan    analytical    cardiovascular    protein    techniques    throughput    data    automated    biological    diagnostics   

 Obiettivo del progetto (Objective)

'Glycosylation is a post-translational modification that enriches protein complexity and function. Dysregulation of glycosylation is associated with a wide range of diseases, including cancer, diabetes, as well as congenital, cardiovascular, immunological and infectious disorders. A number of studies identified potentially important glycan disease biomarkers. With regard to biotechnology, proper glycosylation of biologicals is important, as deviations in glycosylation are known to be associated with adverse drug reactions and reduced therapeutic efficacy. However, glycomics is significantly lagging behind genomics and proteomics, mainly due to the absence of high-throughput analytical methods which can reliably quantify a multitude of glycan structures in complex biological samples. We are confident that by coordinated efforts of leading European scientists in glycan analysis using HPLC, MS and CGE-LIF technologies this project will make a decisive step forward by developing real high-throughput tools for glycosylation analysis. By teaming up with leading European researchers in the field of genome wide association studies this project will perform validation of all methods on extremely well characterized set of samples resulting from the FP6 EuroSpan project. The addition of the newly generated glycome data to the pre-existing information about these individuals will enable development of methods for the systems biology approach analysis of the glycome which will integrate glycomic, genomic and environmental data about thousands of individuals. The same methods will also be adapted for quality control and monitoring in the production of biopharmaceuticals. Strong participation of SMEs in the project and close contacts with large industrial partners will ensure that research accomplishments achieved by collaboration between academic and industrial scientists are swiftly transformed into innovative products and services for the benefit of European industry.'

Introduzione (Teaser)

European researchers are working on an automated high-throughput method for analysing protein glycosylation. The technology is anticipated to advance current diagnostics and aid the discovery of disease-specific biomarkers.

Descrizione progetto (Article)

Protein glycosylation - the addition of sugar moieties - plays an important role in determining the stability of proteins and guiding them to specific subcellular compartments. Alterations in glycan structure can modulate the activity of proteins and are strongly linked to diseases such as cancer, diabetes and cardiovascular disorders. In addition, glycoproteins can serve as useful clinical biomarkers in diagnostics as well as targets for disease therapy.

To address the increasing medical need for the characterisation of protein glycosylation, the EU-funded http://www.highglycan.eu/ (HIGHGLYCAN) (Methods for high-throughput (HTP) analysis of protein glycosylation) project is in the process of developing analytical methods for reliably quantifying a multitude of glycan structures in complex biological samples. In this context, they will use ultrahigh-performance liquid chromatography, capillary gel electrophoresis with laser-induced fluorescence detection, and mass spectrometry.

During the first part of the project, researchers focused on the development of suitable sample preparation methods and techniques for the analysis of protein glycosylation. Several improvements were made in measurement techniques and very good progress was achieved with regard to robotisation and automation of glycomic sample preparation methods. This has culminated in several automated profiling workflows of protein glycosylation, which were validated through the analysis of 1 800 samples. Results were further genetically associated with specific single nucleotide polymorphisms, unambiguously establishing the potential of all these methods in high-throughput biomedical research.

Central to the HIGHGLYCAN study is ensuring that the developed technology gets implemented in biotechnological applications. So far, some of the techniques have been incorporated into industrial glycoanalytical services and production of glycoanalytical kits.

Given the structural complexity of glycosylation and the technology gap, the HIGHGLYCAN glycoprofiling system is a reliable solution for the high-throughput identification and quantitation of glycans. Applications include studying glycosylation changes in diseases such as diabetes and identifying diagnostic biomarkers.

Altri progetti dello stesso programma (FP7-HEALTH)

PARCIVAL (2012)

Partner Network for a Clinically Validated Multi-Analyte Lab-on-a-Chip Platform

Read More  

IBD-CHARACTER (2012)

Inflammatory Bowel Disease CHARACTERization by a multi-modal integrated biomarker study

Read More  

START-UP (2008)

Scientific and technological issues in alternatives research in drug development and Union politics

Read More